Neurocognitive course at two-year follow-up in the neurocognitive assessment in the metabolic and aging cohort (NAMACO) study.

Damas, José; Ledergerber, Bruno; Nadin, Isaure; Tarr, Philip E; Stoeckle, Marcel; Kunze, Ursi; Hauser, Christoph; Gutbrod, Klemens; Calmy, Alexandra; Assal, Frédéric; Schmid, Patrick; Hundsberger, Thomas; di Benedetto, Caroline; Rossi, Stefania; Hasse, Barbara; Schlosser, Ladina; Pasquier, Renaud du; Darling, Katharine E A; Cavassini, Matthias (2021). Neurocognitive course at two-year follow-up in the neurocognitive assessment in the metabolic and aging cohort (NAMACO) study. (In Press). AIDS Wolters Kluwer Health 10.1097/QAD.0000000000003057

[img]
Preview
Text
Neurocognitive_course_at_two_year_follow_up_in_the.96330.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (284kB) | Preview

OBJECTIVE

To examine neurocognitive course over time among people with well-treated HIV.

DESIGN

The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study is an ongoing, prospective, longitudinal, multicenter and multilingual study within the Swiss HIV Cohort Study (SHCS). Participants undergo neuropsychological assessment at baseline and two-yearly follow-up.

SETTING

Seven SHCS centers.

SUBJECTS

Patients aged ≥45 years enrolled in the SHCS with fluency in the local language (French, German or Italian) and agreeing to participate in the NAMACO study: 981 participants at baseline, 720 at two-year follow-up of whom 644 had complete data sets.

INTERVENTION

Standardized neuropsychological assessment at baseline and two-year follow-up.

MAIN OUTCOME MEASURE

Neurocognitive performance using Frascati criteria and mean z-scores.

RESULTS

Four participants (of 644, 0.6%) had plasma HIV-1 RNA > 50 copies/mL; median CD4 count was 660 cells/μL. According to Frascati criteria, 204 participants (31.7%) had neurocognitive impairment (NCI) at baseline. NCI severity in these participants changed little over two years and comprehensive models based on Frascati criteria were not feasible. Examining mean z-scores, however, we observed neurocognitive stability or improvement over two years in five of seven neurocognitive domains assessed. Age ≥65 years (p = 0.02) and cognitive complaints (p = 0.004) were associated with neurocognitive decline, while black race (p = 0.01) and dolutegravir treatment (p = 0.002) were associated with improvement.

CONCLUSION

Frascati criteria were less sensitive in measuring NCI change and therefore unsuitable for following neurocognitive course in our cohort of people with well-treated HIV. Examining neurocognitive course by mean z-score change, we observed stability or improvement.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Hauser, Christoph Victor and Gutbrod, Klemens

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1473-5571

Publisher:

Wolters Kluwer Health

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

14 Sep 2021 14:22

Last Modified:

14 Sep 2021 14:22

Publisher DOI:

10.1097/QAD.0000000000003057

PubMed ID:

34411034

BORIS DOI:

10.48350/158954

URI:

https://boris.unibe.ch/id/eprint/158954

Actions (login required)

Edit item Edit item
Provide Feedback